Targeting the Long Non-Coding RNA LINC00599-205 splicing by novel candidate drug ABX464 to produce the anti-inflammatory microRNA miR-124

Archive ouverte

Manchon, Laurent | Vautrin, Audrey | Garcel, Aude | Campos, Noëlie | Tazi, Jamal

Edité par CCSD ; BiomedGrid, LLC -

International audience. Many nascent long non-coding RNAs have received considerable attention in recent years because of their major regulatory roles in gene expression and signaling pathways at various levels. Indeed long non-coding RNAs undergo the same maturation steps as pre-mRNAs of protein-coding genes, but they are less efficiently spliced and polyadenylated in comparison to them. Here we focus on a specific human long non-coding RNA and we show the activity of a new candidate drug that potentially affect its splicing and generate an anti-HIV and anti-inflammatory effects driven by upregulation of microRNA biogenesis. To investigate this activity we combine the use of capture sequencing technology and an ab initio transcript assembly on cells from six healthy individuals. The sequencing depth of capture sequencing permitted us to assemble transcripts exhibiting a complex array of splicing patterns. In essence, we revealed that splicing of the long non-coding RNA is activated by the drug whereas this splicing was not present in untreated samples.

Suggestions

Du même auteur

Both anti-inflammatory and antiviral properties of novel drug candidate ABX464 are mediated by modulation of RNA splicing

Archive ouverte | Vautrin, Audrey | CCSD

International audience. ABX464 is a first-in-class, clinical-stage, small molecule for oral administration that has shown strong anti-inflammatory effects in the DSS-model for inflammatory bowel disease (IBD) and al...

ABX464 (obefazimod) up-regulates miR-124 to reduce pro-inflammatory markers in inflammatory bowel diseases

Archive ouverte | Apolit, Cécile | CCSD

International audience. Advanced therapies have transformed the treatment of inflammatory bowel disease; however, many patients fail to respond, highlighting the need for therapies tailored to the underlying cell an...

Long lasting control of viral rebound with a new drug ABX464 targeting Rev - mediated viral RNA biogenesis

Archive ouverte | Campos, Noëlie | CCSD

International audience. Background: Current therapies have succeeded in controlling AIDS pandemic. However, there is a continuing need for new drugs, in particular those acting through new and as yet unexplored mech...

Chargement des enrichissements...